Key Highlights
- Amgen shares are trading up 5.86% today to $412.87, extending Tuesday's 5.81% gain and moving toward 52-week highs.
- Second-quarter total revenue exceeded $10 billion, a 10% year-over-year increase, with adjusted EPS of $6.29 beating the $5.62 consensus estimate.
- Twenty-two products delivered double-digit sales growth, with 17 products now annualizing at more than $1 billion in sales.
- Repatha sales grew 37% year-over-year to $953 million, while EVENITY sales rose 38% to $714 million.
- Management raised full-year 2026 guidance to $38.2 billion to $39.4 billion in revenue and non-GAAP EPS of $22.30 to $23.50.
What's Driving Shares Today
Amgen (NASDAQ:AMGN) is a leading global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California, dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. Its extensive product portfolio spans oncology and hematology, inflammatory diseases, bone health, cardiovascular disease, nephrology, and neuroscience, featuring well-known brands such as Enbrel, Prolia, Otezla, Repatha, XGEVA, Neulasta, KYPROLIS, and BLINCYTO.
Shares are trading near 52-week highs today as momentum from Tuesday's strong second-quarter results continues to drive buying interest. Total revenues exceeded $10 billion, a 10% year-over-year increase, with adjusted EPS of $6.29 beating consensus estimates of $5.62, driven by 37% growth in Repatha, 38% growth in EVENITY, and strong rare-disease and oncology franchise performance.
Six Key Growth Drivers Lead the Quarter
CEO Robert Bradway said the strong results were driven by the breadth and depth of Amgen's portfolio, highlighting the company's ability to grow through patent expirations and increased competition. The company's six key growth drivers, Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, and biosimilars, grew 26% year-over-year collectively and represented nearly 70% of product sales. TEZSPIRE sales rose 42% to $486 million, UPLIZNA sales increased 90% to $335 million, and IMDELLTRA sales grew 115%, establishing itself as a best-in-class treatment for small cell lung cancer.
Legacy bone-health products continue to face biosimilar competition, with Prolia and XGEVA combined sales declining 33% year-over-year to $1.1 billion. The company's biosimilars portfolio, however, grew 29% year-over-year, with PAVBLU sales up 121%, helping offset the pressure from loss of exclusivity in older products.
Raised Guidance and Pipeline Progress
Management raised full-year 2026 guidance to $38.2 billion to $39.4 billion in total revenue, above the roughly $37.7 billion analyst consensus, and non-GAAP EPS of $22.30 to $23.50. Late-stage pipeline progress includes MariTide advancing through nine ongoing and planned Phase 3 studies in obesity and cardiometabolic disease, olpasiran enrolling 7,297 patients in the OCEAN(a) outcomes trial for elevated Lp(a), and dazodalibep in two Phase 3 Sjogren's studies with data expected in the second half of 2026.
The company also announced a leadership transition, with CFO Peter Griffith departing and Thomas Dittrich, a returning Amgen finance veteran, taking over the CFO role ahead of the next earnings call.
Conclusion
Amgen's broad-based growth across 22 products, combined with a raised full-year guidance and continued late-stage pipeline execution on MariTide and other candidates, suggests the company's diversified portfolio strategy continues to offset pressure from biosimilar competition in legacy products. With shares extending gains toward 52-week highs today, investors appear to be rewarding the durability of this growth story heading into the back half of 2026.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...